Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.

Wirth, LJ; Eigendorff, E; Capdevila, J; Paz-Ares, LG; Lin, CC; Taylor, MH

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索